Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Molecular models advance the fight against malaria

26.04.2005


Research from Dartmouth Medical School, demonstrating how malaria parasites form mutations that make them stubbornly resistant to drug therapy, may hold the key to a new treatments for a disease that afflicts more than half a billion people worldwide.



The scientists developed disease models using yeast and successfully introduced five mutations that make malaria resistant to the anti-malarial drug, atovaquone. The study, featured as the cover story of the April 29 Journal of Biological Chemistry, paves the way for using these models to test new drugs that could suppress malaria’s ability to mutate against current therapy. "This is the first quantitative explanation for malaria’s drug resistance," said Dr. Bernard Trumpower, professor of biochemistry at Dartmouth Medical School and head of the study. "In addition to confirming the belief that the resistance was due to these mutations, we have created a practical research tool to design new, improved versions of the drug using these resistant strains."

Malaria, transmitted by Plasmodium falciparum, a parasite carried by mosquitoes, has developed resistance to almost every anti-malarial drug introduced in the past 30 years. Although atovaquone is one of the most recent drugs on the market, there is significant evidence that malaria parasites are quickly developing resistance to that drug as well. According to WHO estimates, 40% of the world’s population are currently at risk of the disease and approximately 2 million people, mostly children, are killed by malaria annually worldwide. Today marks Africa Malaria Day, organized to promote awareness of the disease in a country where a child is killed every 30 seconds by malaria.


Investigating ways to counter the mutations and sustain the efficacy of anti-malarial drugs, Trumpower and his colleagues continued their work on previous studies using yeast enzymes to explore atovaquone resistance. It is not possible to grow enough malaria parasites to isolate and study the respiratory enzyme cytochrome bc1 complex, which the parasites need to live and multiply. A protein subunit of the bc1 complex is where the malaria parasite mutates to counter anti-malarial drug therapies. Yeast is an effective resource because it can be safely grown in large quantities and can be easily modified to take on the qualities of more dangerous pathogens, without risking human infection.

When the researchers genetically transferred mutations into the yeast surrogates, the yeast acquired resistance to atovaquone just as the malaria parasites had done. The team was then able to apply computerized modeling techniques to illustrate exactly how the drug interacted with the cytochrome bc1 complex – the respiratory enzyme the parasites need to live and multiply -- on a molecular level. With this new understanding of how the parasites were able to counter the effects of atovaquone, researchers can now design new anti-malarial drugs with features making the appearance of resistance more unlikely.

"Within the next 3-5 years, we hope to develop a new drug that will finally empower us to treat this terrible disease," said Trumpower.

Dartmouth Medical School co-authors of the paper are Dr. Jacques Kessl, research associate in biochemistry, Kevin Ha, Anne Merritt and Benjamin Lange. Other co-authors are Dr. Brigitte Meunier and Philip Hill from the Wolfson Institute for Biomedical Research in London and Dr. Steven Meshnick from the University of North Carolina, Chapel Hill.

Andrew Nordhoff | EurekAlert!
Further information:
http://www.dartmouth.edu

More articles from Life Sciences:

nachricht A Map of the Cell’s Power Station
18.08.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau

nachricht On the way to developing a new active ingredient against chronic infections
18.08.2017 | Deutsches Zentrum für Infektionsforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>